BeiGene (rebranded BeOne Medicines in 2025) is a global oncology company founded in 2010 that discovers, develops, manufactures and commercializes innovative and affordable cancer medicines. It has one of the world's largest oncology research teams and more than 9,000 employees across multiple continents. Its lead product is the BTK inhibitor zanubrutinib (Brukinsa).